Efficacy and Safety of Single‐ or Double‐Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta‐Analysis

• Published in: Journal of cellular biochemistry Vol. 118; no. 12; pp. 4536 - 4547
• Main Authors: Yang, Xi‐Ling, Duo‐Ji, Mi‐Ma, Long, Zi‐Wen
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-12-2017
• Subjects: ANTIDIABETIC DRUGS; Antidiabetics; BAYESIAN NETWORK MODEL; Confidence intervals; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Drug Therapy, Combination - methods; Effectiveness; EFFICACY; Female; Humans; Hypoglycemic Agents - therapeutic use; Male; Meta-analysis; Metformin; Pioglitazone; RANDOMIZED CONTROLLED TRIALS; Randomized Controlled Trials as Topic; Ranking; SAFETY; Therapy; TYPE 2 DIABETES MELLITUS; BAYESIAN NETWORK MODEL; EFFICACY; ANTIDIABETIC DRUGS; SAFETY; RANDOMIZED CONTROLLED TRIALS; TYPE 2 DIABETES MELLITUS
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.26115

ABSTRACT
A network meta‐analysis was performed in order to compare the efficacy and safety of single‐ or double‐drug antidiabetic regimens in the treatment of type 2 diabetes mellitus (T2DM). PubMed and Cochrane Library searches were conducted since inception to February 2017. Randomized controlled trials (RCTs) of different antidiabetic regimens in the treatment of T2DM were included in this study. Direct and indirect evidences were combined to calculate the odds ratio (OR) or weighted mean difference (WMD) and its 95% confidence interval (95%CI), and in order to draw the surface under the cumulative ranking curves (SUCRA). A total of 19 RCTs meeting our inclusion criteria were finally incorporated into our network meta‐analysis, including 19 single‐ or double‐drug antidiabetic regimens. The network meta‐analysis showed that the anti‐hyperglycemic effects of Sitagliptin + Metformin, Empagliflozin + Metformin, Exenatide + Metformin, Vildagliptin + Metformin, Taspoglutide + Metformin, and Pioglitazone + Metformin were better than individual Metformin regimens. Dulaglutide + Metformin and Taspoglutide + Metformin regimens were comparatively less safe than individual Metformin regimens. The cluster ranking analysis based on SUCRA values suggested that Taspoglutide + Metformin regimens had best efficacy and worst safety among the different therapy regimens. Our data confirmed previous observations and suggested that Taspoglutide + Metformin regimen may have better efficacy for the treatment of T2DM among 19 therapy regimens, while its incidence of adverse events was relatively higher. J. Cell. Biochem. 118: 4536–4547, 2017. © 2017 Wiley Periodicals, Inc.
Our data confirmed previous observations and suggested that the taspoglutide + metformin regimen may have better efficacy for the treatment of T2DM among 19 therapy regimens, while its incidence of adverse events was relatively higher.